Our latest publications
Burger EA, Pedersen K, Stephen S, Kristiansen IS, Kim JJ. Choosing wisely: a model-based analysis evaluating the trade-offs in cancer benefit and diagnostic referrals among alternative HPV testing strategies in Norway. British Journal of Cancer (2017). doi: 10.1038/bjc.2017.248
Pedersen K, Burger EA, Campbell S, Nygård M, Aas E, Lönnberg S. Advancing the evaluation of cervical cancer screening: development and application of a longitudinal adherence metric. European Journal of Public Health (2017). doi: https://doi.org/10.1093/eurpub/ckx073
Burger EA, Kim JJ, Sy S, Castle PE. Age of acquiring causal human papillomavirus (HPV) infections: Leveraging simulation models to explore the natural history of HPV-induced cervical cancer. Clinical Infectious Diseases (2017). doi: https://doi.org/10.1093/cid/cix475
Norwegian Technical Appendix. Cervical Cancer Natural History Model Calibration and Costing Approach for Norway. Technical Appendix, 2017. [PDF]
Cervical Cancer Natural History Model Calibration and Costing Approach for Norway. Technical Appendix, 2016. [PDF]
Burger EA, Sy S, Nygård N, Kim JJ. The cost-effectiveness of cervical self-sampling to improve routine cervical cancer screening: The importance of respondent screening history and compliance. Cancer Epidemiology Biomarkers and Prevention (2016).
Castle P, Burger EA. Age of HPV vaccination? Lancet Infectious Diseases (2016).
Kim JJ, Burger EA, Sy S, Campos N. Optimal cervical cancer screening in women vaccinated against human papillomavirus. JNCI (2016).
Burger EA, Lee K, Saraiya M, Thompson TD, Chesson HW, Markowitz LE, Kim JJ. Racial and thnic disparities in human papillomavirus-associated cancer burden with first-generation and second-generation human papillomavirus vaccines. Cancer (2016) 122(13), s 2057-2066. doi: 10.1002/cncr.30007.
Pedersen K, Burger EA, Sy S, Kristiansen IS, Kim JJ. Cost-effective management of women with minor cervical lesions: Revisiting the application of HPV DNA testing. Gynecologic Oncology (2016). doi: 10.1016/j.ygyno.2016.08.231.
Pedersen K, Sørbye SW, Kristiansen IS, Burger EA. Using novel biomarkers to triage young adult women with minor cervical lesions: A cost-effectiveness analysis. BJOG - an International Journal of Obstetrics and Gynaecology. (2016). doi: 10.1111/1471-0528.14135.
Pedersen K, Sørbye SW, Burger EA, Lönnberg S, Kristiansen IS. Using Decision-Analytic Modeling to Isolate Interventions That Are Feasible, Efficient and Optimal: An Application from the Norwegian Cervical Cancer Screening Program. Value in Health. (2015). 18(8): 1088-1097.
Pedersen K, Lönnberg S, Skare GB, Sørbye SW, Burger EA, Kristiansen IS. Kostnader ved Masseundersøkelsen mot livmorhalskreft. Sykepleien Forskning. (2015) ISSN 1890-2936, s 62-71. doi: 10.4220/Sykepleienf.2015.53414
Burger EA, Sy S, Nygård M, Kristiansen IS, Kim JJ. Prevention of HPV-related cancers in Norway: Too late to vaccinate? The incremental benefits and cost-effectiveness of a delayed catch-up program using the 4-valent HPV vaccine in Norway. Journal of Infectious Diseaseas. (2015). 211(2): 206-15
Burger EA, Kim JJ. The value of improving failures within a cervical cancer screening program: An example from Norway. Int J Cancer. (2014). 135(8): 1931-9
Burger EA, Sy S, Nygård M, Kristiansen IS, Kim JJ. Prevention of HPV-related cancers in Norway: Cost-effectiveness of expanding the HPV Vaccination program to include pre-adolescent boys. PLOS One. (2014). 9:3:e89974
Burger EA, Nygård M, Gyrd-Hansen D, Moger TA, Kristiansen IS. Does the primary screening test influence women's anxiety and intention to screen for cervical cancer? A randomized survey of Norwegian women. BMC Public Health. (2014). 14: 360
Burger EA, Ortendahl JD, Sy S, Kristiansen IS, Kim JJ. Cost-effectiveness of cervical cancer screening with primary human papillomavirus (HPV) testing in Norway. British J of Cancer. (2012). 106(9): 1571-8
Burger EA, et al. HPV mRNA tests for the detection of cervical intraepithelial neoplasia: A systematic review. Gynecologic Oncology. (2010). 120(3): 430-8